Inflammatory Diseases: Recent Advances in Basic and Translational Research and Therapeutic Treatments

Organized by Chen Dong of MD Anderson Cancer Center, Jingwu Zhang Zang of GlaxoSmithKline, Tadamitsu Kishimoto of Osaka University and Richard A. Flavell of Yale University School of Medicine, the conference will:
• Analyze the cellular and molecular basis of various inflammatory responses, review advances in the development of therapeutics such as small molecule drugs for a wide range of inflammatory diseases, and provide a single forum for basic, clinical and industrial experts to consider opportunities for further development of concepts, systems and therapeutics;
• Feature roundtable discussions on ways to improve animal models and approaches to study human diseases and drug responses;
• Provide opportunities for inter-disciplinary collaboration through shared sessions with the joint meeting on “Emerging Cytokine Networks.”

+ show speakers and program
Keynote Session (Joint)
Ruslan M. Medzhitov, HHMI, Yale University School of Medicine, USA
Inflammation

Fiona M. Powrie, University of Oxford, UK
Cytokine Network Regulating Adaptive and Innate Immunity

Richard A. Flavell, Yale University School of Medicine, USA
Inflammasome in Inflammatory and Metabolic Diseases

Diane J. Mathis, Harvard Medical School, USA
Microbiota in Regulation of Inflammatory Diseases

Yong-Jun Liu, Baylor Research Institute, USA
Regulators of Th2 Immunity

David Artis, University of Pennsylvania School of Medicine, USA
Innate Lymphocytes and Mucosal Immunity

John G. Matthews, Genentech, Inc., USA
Lebrikizumab (Anti-IL-13) Treatment for Asthma

Hergen Spits, University of Amsterdam, Netherlands
Regulation of ILC Subsets

Yasmine Belkaid, NIAID, National Institutes of Health, USA
Skin Commensals Regulation of Local Immunity

Hilde Cheroutre, La Jolla Institute for Allergy and Immunology, USA
New Emerging Transcription Factor and Cytokine Networks at the Mucosal Interface of the Intestine

Shimon Sakaguchi, Osaka University, Japan
Roles of Treg Cells in Inflammation

Chen Dong, MD Anderson Cancer Center, USA
Regulation and Modulation of Th17 Cells in Inflammation

Carola G. Vinuesa, Australian National University, Australia
T Follicular Helper Cells in Inflammatory Diseases

Jingwu Zhang Zang, GlaxoSmithKline, China
Novel Targets in MS

Richard M. Locksley, HHMI/University of California, San Francisco, USA
Innate Helper Cells in Lung Immunity

Gabriel Nuñez, University of Michigan, USA
Cytokines and Purinergic P2X7 Receptor

Andreas Diefenbach, University of Freiburg, Germany
Transcriptional Regulation of ILC Subsets

Marco Colonna, Washington University School of Medicine, USA
Regulation of ILC and NK Subsets

Pankaj Gupta, Pfizer, USA
Jak Inhibitor in Rheumatoid Arthritis

Volker Brinkmann, Novartis Institutes for BioMedical Research, Switzerland
S1P Modulator as Treatment for MS

John Bertin, GlaxoSmithKline, USA
RIP Kinase Inhibitors as Therapeutics for Inflammatory Diseases

Jason G. Cyster, HHMI/University of California, San Francisco, USA
Leukocyte Migration to Skin

Fumio Takei, British Columbia Cancer Agency, Canada
ILC-2 Regulation of Allergic Diseases

Jay K. Kolls, University of Pittsburgh School of Medicine, USA
Adaptive and Innate Response in Respiratory Infection

David A. Hafler, Yale School of Medicine, USA
T Cells in MS

Virginia Pascual, Baylor Institute for Immunology Research, USA
Systemic Approaches in Systemic Disease

Farrah Kheradmand, Baylor College of Medicine, USA
Pathways Driving Chronic Inflammation in COPD

Howard L. Weiner, Brigham & Women’s Hospital, USA
Treatment of Inflammatory and Autoimmune Diseases by Mucosal Induction of Regulatory T Cells

Marc Veldhoen, Babraham Institute, UK
Influence of Environmental Factors on Lymphocyte Biology

Vijay K. Kuchroo, Brigham and Women's Hospital, Harvard Medical School, USA
Control of Treg and Th17 Cell Development

Federica Sallusto, Institute for Research in Biomedicine, Switzerland
Cytokine Regulation of Human T Cell Subsets

Max D. Cooper, Emory University, USA
Evolutionary Conserved Immune Sensors

Michael Karin, University of California, San Diego, USA
NF-kappaB in Cancer

Raymond N. DuBois, Arizona State University, USA
Inflammation in Colon Cancer

Lisa M. Coussens, Oregon Health & Sciences University, USA
Inflammation in Breast Cancer

Drew M. Pardoll, Johns Hopkins University School of Medicine, USA
Hypoxia Response and Th17 Regulation

Silvia Monticelli, Institute for Research in Biomedicine, Switzerland
Mast Cells

K. Mark Ansel, University of California, San Francisco, USA
miRNA Regulation in Immunity

Tadamitsu Kishimoto, Osaka University, Japan
IL-6: From Bench to Bedside

Dhavalkumar D. Patel, Novartis Institutes for BioMedical Research, Switzerland
Treatment of Inflammatory Diseases with Anti-IL-17

Daniel J. Cua, Merck Research Laboratories, USA
Targeting IL-23 in Inflammation and Cancer

Ira Mellman, Genentech, Inc., USA
Anti-PDL in Cancer Immunotherapy

Jeffrey A. Bluestone, University of California, San Francisco, USA
Anti-CD3 Therapy

Bruce R. Blazar, University of Minnesota, USA
Treg Therapy

Stephen D. Miller, Northwestern University Medical School, USA
Use of Carboxylated PLG Nanoparticles for Tolerance Induction and Treatment of Inflammatory Monocyte-Mediated Diseases

John J. O'Shea, NIAMS, National Institutes of Health, USA
Targeting Cytokine Signaling: That's a Fact, Jak

Adrian C. Hayday, King's College London School of Medicine, UK
The Contribution of gammadelta T Cells to Afferent Immunogenicity in Mice and in the Clinic

Maria Grazia Roncarolo, San Raffaele Scientific Institute, Italy
Cell-Based Immune Therapy

17 Jan - 22 Jan 2014
Vancouver
Canada
meeting website